Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced that it will carry out a 1-for-50 reverse stock split of its common shares after filing a Certificate of Amendment in Delaware on March 3, 2026. The split is scheduled to take effect on March 6, 2026, following shareholder approval granted on February 19.
The action will consolidate the company’s roughly 202.4 million outstanding shares on a proportional basis. While the number of shares in circulation will decline accordingly, the total authorized share count and shareholders’ proportional ownership will remain unchanged, aside from minor adjustments resulting from cash payments in place of fractional shares.
According to the company, the reverse split was approved by the board as a measure to help restore compliance with Nasdaq’s minimum bid price requirement of $1.00. Trading will continue under the existing ticker symbol TVGN, though the shares will begin trading on a split-adjusted basis and will carry a new CUSIP identifier.
The company also noted that all outstanding equity awards, warrants, and convertible preferred stock will be modified to reflect the new share ratio. The adjustment will not affect Tevogen’s underlying business operations or the total equity held by shareholders, but it is intended to support the company’s continued Nasdaq listing and potentially improve market perception.
More about Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a healthcare-focused company that aims to combine affordability, operational efficiency, and scientific innovation in the development of advanced therapeutics. Through its Tevogen Bio and Tevogen.AI platforms, the company integrates artificial intelligence with precision T-cell therapy technologies to develop treatments targeting areas such as virology, oncology, and neurology, while also pursuing scalable solutions for broader healthcare challenges.